OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
OpGen Stock Performance
OpGen stock opened at $0.62 on Friday. The stock has a market cap of $28.87 million, a P/E ratio of -0.73 and a beta of -0.37. The company has a current ratio of 1.76, a quick ratio of 1.69 and a debt-to-equity ratio of 0.23. The stock has a 50 day moving average of $0.56 and a 200-day moving average of $0.66. OpGen has a 52 week low of $0.31 and a 52 week high of $3.72.
OpGen (NASDAQ:OPGN - Get Rating) last released its earnings results on Thursday, May 12th. The medical research company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.01. The company had revenue of $0.47 million during the quarter, compared to analysts' expectations of $1.05 million. OpGen had a negative return on equity of 72.67% and a negative net margin of 680.36%. On average, analysts expect that OpGen will post -0.54 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on OPGN shares. Alliance Global Partners downgraded shares of OpGen to a "neutral" rating in a research report on Tuesday, July 19th. StockNews.com started coverage on shares of OpGen in a research report on Friday. They issued a "sell" rating for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price objective on shares of OpGen in a research report on Friday, June 10th.